从2020年国内外主要指南更新变化解读胃肠间质瘤精准诊治

Interpretation of the precise diagnosis and treatment of gastrointestinal stromal tumors from the latest updates of domestic and international guidelines in 2020

酪氨酸激酶受体抑制剂在GIST中取得成功是精准医学时代分子靶向药物治疗的里程碑。2020年,国内外各学术组织围绕GIST的诊疗实践相继发布或更新了各种诊疗指南与专家共识。其中在指南层面,中国临床肿瘤学会(CSCO)发布我国首部GIST诊疗指南《胃肠间质瘤诊疗指南2020》,美国国家综合癌症网络也对NCCN指南GIST部分内容作出重要更新,二者更新均由最新循证医学证据更新所驱动,将对我国GIST精准诊疗实践产生重要影响。

The success of tyrosine kinase receptor inhibitors(TKI)in gastrointestinal stromal tumor(GIST)is a milestone of molecular targeted drug therapy in the era of precision medicine.At present,various international and domestic academic organizations have issued various diagnosis and treatment guidelines and expert consensus around the diagnosis and treatment practice of GIST.In 2020,various international and domestic academic organizations have issued or updated various diagnosis and treatment guidelines and expert consensus around the diagnosis and treatment practice of GIST.At the guideline level,Chinese society of Clinical Oncology(CSCO)issued the first"Guideline for Diagnosis and Treatment of Gastrointestinal Stromal Tumor 2020"in China,National Comprehensive Cancer Network(NCCN)of the United States also made important updates on the part of GIST in NCCN guidelines.The update of the above guidelines is driven by the update of the latest evidence-based medicine,which will have important impacts on the practice of precise diagnosis and treatment of GIST in China.